The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of ...

Keytruda sales account for roughly 40% of Merck’s revenue, and the company has been focused on the 2028 patent expiration for ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication ...

Merck accelerates subcutaneous Keytruda rollout to protect cancer drug's dominance as IV patent nears 2028 expiry.

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve ...

An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers ...

Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Summit Therapeutics (SMMT – Research Report), retaining the price target ...

“Our pipeline is broadening. I think that is an important part of thinking about the future of Merck beyond 2028,” said Dr.

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.